OBJECTIVE: To elucidate the mechanism and the binding regions of monoclonal antibodies (MA) that interfere with thrombin-activatable fibrinolysis inhibitor (TAFI)/activated thrombin-activatable fibrinolysis inhibitor (TAFIa) activity. RESULTS: Of 42 MA, 19 interfere with the TAFI activation/TAFIa activity resulting in an inhibition of up to 92%. Characterization of the mechanism of inhibition revealed that 14 MA blocked the activation of TAFI by thrombin/thrombomodulin completely whereas five MA interfered directly with the enzymatic activity of TAFIa. Surprisingly, the former, except one, induced a significant reduction of clot lysis time whereas the latter did not. Affinity studies using a human/murine TAFI chimer revealed that the binding region of the 14 activation blocking MA is located between AA1 and AA67. MA that inhibit exclusively the activation of TAFI by thrombin/thrombomodulin bind to Gly66. A MA that inhibits the activation of TAFI by both thrombin/thrombomodulin and plasmin binds to Val41. The MA that interfere with the enzymatic activity bind to the TAFIa moiety. CONCLUSIONS: The current study reveals at least three different putative molecular targets in the search for pharmacologically active compounds to modulate TAFIa activity.
OBJECTIVE: To elucidate the mechanism and the binding regions of monoclonal antibodies (MA) that interfere with thrombin-activatable fibrinolysis inhibitor (TAFI)/activated thrombin-activatable fibrinolysis inhibitor (TAFIa) activity. RESULTS: Of 42 MA, 19 interfere with the TAFI activation/TAFIa activity resulting in an inhibition of up to 92%. Characterization of the mechanism of inhibition revealed that 14 MA blocked the activation of TAFI by thrombin/thrombomodulin completely whereas five MA interfered directly with the enzymatic activity of TAFIa. Surprisingly, the former, except one, induced a significant reduction of clot lysis time whereas the latter did not. Affinity studies using a human/murineTAFI chimer revealed that the binding region of the 14 activation blocking MA is located between AA1 and AA67. MA that inhibit exclusively the activation of TAFI by thrombin/thrombomodulin bind to Gly66. A MA that inhibits the activation of TAFI by both thrombin/thrombomodulin and plasmin binds to Val41. The MA that interfere with the enzymatic activity bind to the TAFIa moiety. CONCLUSIONS: The current study reveals at least three different putative molecular targets in the search for pharmacologically active compounds to modulate TAFIa activity.
Authors: Evelien Vandevenne; Stefanie Christiaens; Sandy Van Buggenhout; Ruben P Jolie; Margarita González-Vallinas; Thomas Duvetter; Paul J Declerck; Marc E Hendrickx; Ann Gils; Ann Van Loey Journal: Planta Date: 2010-11-03 Impact factor: 4.116
Authors: Chengliang Wu; Paul Y Kim; Reg Manuel; Marian Seto; Marc Whitlow; Mariko Nagashima; John Morser; Ann Gils; Paul Declerck; Michael E Nesheim Journal: J Biol Chem Date: 2008-12-12 Impact factor: 5.157
Authors: Adam Miszta; Anna K Kopec; Asmita Pant; Lori A Holle; James R Byrnes; Daniel A Lawrence; Kirk C Hansen; Matthew J Flick; James P Luyendyk; Bas de Laat; Alisa S Wolberg Journal: Blood Date: 2020-05-07 Impact factor: 22.113
Authors: Maarten Bloemen; Thomas Van Stappen; Pieter Willot; Jeroen Lammertyn; Guy Koeckelberghs; Nick Geukens; Ann Gils; Thierry Verbiest Journal: PLoS One Date: 2014-10-02 Impact factor: 3.240
Authors: Katherine Bridge; Charlotte Revill; Fraser Macrae; Marc Bailey; Nadira Yuldasheva; Stephen Wheatcroft; Roger Butlin; Richard Foster; D Julian Scott; Ann Gils; Robert Ariens Journal: PLoS One Date: 2017-05-04 Impact factor: 3.240